Jacob Gottlieb’s Altium Capital

Jacob Gottlieb, former founder and CIO of Visium Asset Management now resides as the founder of his new firm, Altium Capital. Gottlieb is using his vast experience and success as a businessman and investor to replicate his former success with the new firm.

As a young man, Gottlieb intended to peruse a medical career. He graduated from Brown University with a BA in Economics as well as an MD from NYU Medical School. Following attaining his medical degree, Gottlieb completed an internship at St. Vincent’s Hospital, which enlightened him; he came to the realization that he preferred a financial career in wall street over his current career path.

Gottlieb began his career as a buy-side analyst at Stanford C. Bernstein & Co while conversely continuing his education. He obtained his Certified Financial Analyst (CFA) classification in 2001 and left his job at Stanford to become a portfolio manager at Merlin Biomed Group, quickly followed by a job at Balyasny Asset Management (BAM).

His success at BAM convinced Gottlieb to start Visium, a hedge fund firm, in 2005. With a trusted founding team, Gottlieb raised $300 million in seed capital. Visium eventually grew to become an 8$ billion-dollar fund with 170 employees.

Visium was abruptly closed by Gottlieb in 2016 when three employees were charged for securities mismarking and insider trading. The employee’s actions created misinformation regarding return rates, as well as inflated management fees. The charges caused fear leading investors and employees to leave the company, which in turn caused Gottlieb to close the company.

Despite this blow, Gottlieb has turned his attention and effort into his new investment firm, Altium Capital. Due to his extensive experience, Gottlieb has a large network of professionals, and opened a New York City office shared with Iguana Healthcare Partners and Bay City Capital. Altium is beginning its portfolio with late-stage pharmaceutical companies, Oramed Pharmaceuticals Inc. and Sellas Life Sciences. Both the companies have new products in the final stages of FDA approval with a large potential to become a significant player in the medical field, making these first pivotal investments strategic in nature.